Total Payments
$186,754
2024 Payments
$30,909
Companies
25
Transactions
227
Payment Breakdown by Category
Consulting$92,749 (49.7%)
Other$55,002 (29.5%)
Travel$22,275 (11.9%)
Research$7,428 (4.0%)
Food & Beverage$7,037 (3.8%)
Education$2,263 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $92,749 | 45 | 49.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,670 | 14 | 17.0% |
| Honoraria | $23,331 | 11 | 12.5% |
| Travel and Lodging | $22,275 | 71 | 11.9% |
| Unspecified | $7,428 | 14 | 4.0% |
| Food and Beverage | $7,037 | 70 | 3.8% |
| Education | $2,263 | 2 | 1.2% |
Payments by Type
General
$179,325
213 transactions
Research
$7,428
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $28,527 | 53 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $18,567 | 22 | $0 (2024) |
| Roche Products Limited | $16,475 | 11 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $14,547 | 31 | $0 (2020) |
| Shire North American Group Inc | $14,380 | 26 | $0 (2019) |
| Merck Sharp & Dohme LLC | $12,796 | 12 | $0 (2023) |
| F. Hoffmann-La Roche AG | $12,723 | 11 | $0 (2019) |
| Tris Pharma Inc | $10,629 | 8 | $0 (2024) |
| Alkermes, Inc. | $9,923 | 9 | $0 (2021) |
| Daiichi Sankyo Company LTD | $7,773 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,909 | 37 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($13,687) |
| 2023 | $23,221 | 21 | Merck Sharp & Dohme LLC ($12,796) |
| 2022 | $6,225 | 6 | Tris Pharma Inc ($3,500) |
| 2021 | $8,911 | 7 | Tris Pharma Inc ($5,000) |
| 2020 | $16,779 | 15 | Alkermes, Inc. ($7,123) |
| 2019 | $28,199 | 35 | Roche Products Limited ($8,813) |
| 2018 | $35,823 | 41 | Daiichi Sankyo Company LTD ($7,773) |
| 2017 | $36,686 | 65 | Sunovion Pharmaceuticals Inc. ($14,178) |
All Payment Transactions
227 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $101.45 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $85.08 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $5,150.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $414.46 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $375.76 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $200.09 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 11/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| 10/16/2024 | Tris Pharma Inc | Onyda XR (Drug) | Food and Beverage | In-kind items and services | $48.33 | General |
| Category: ADHD | ||||||
| 10/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $45.77 | General |
| Category: NEUROSCIENCE | ||||||
| 09/30/2024 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,375.00 | General |
| 07/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 05/28/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 05/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: PSYCHIATRY | ||||||
| 04/19/2024 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 04/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,044.00 | General |
| 04/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Travel and Lodging | Cash or cash equivalent | $56.84 | General |
| 03/29/2024 | Sumitomo Pharma Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 02/29/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $124.97 | General |
| 02/29/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $61.81 | General |
| 02/29/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $48.38 | General |
| 02/29/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $48.27 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CNS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Functional Neuroimaging Study to Evaluate the Treatment Effect of SPN-810 Extended-Release Molindone on Impulsive Aggression IA in Patients with Attention-DeficitHyperactivity Disorder ADHD in Conjunction with Standard ADHD Treatment | Supernus Pharmaceuticals, Inc. | $1,624 | 3 |
| Evaluation of SPN-812 ER 200 and 400 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial | Supernus Pharmaceuticals, Inc. | $1,192 | 5 |
| "A Phase IV Unequal Randomization Double-Blind Study To Evaluate the Dose Tolerance and Safety of Extended-Release Equetro (carbamazepine) versus Placebo Followed by an Open-Label and Long Term-Maintenance Treatment in Children and Adolescents Aged 10-17 years Diagnosed with Acute Manic or Mixed Bipolar I Disorder" | Validus Pharmaceuticals LLC | $967.10 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT | Supernus Pharmaceuticals, Inc. | $425.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS 13-17 YEARS OLD WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $20.25 | 1 |
About Dr. Robert Findling, MD
Dr. Robert Findling, MD is a Child & Adolescent Psychiatry healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174549679.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Findling, MD has received a total of $186,754 in payments from pharmaceutical and medical device companies, with $30,909 received in 2024. These payments were reported across 227 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($92,749).
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location Cleveland, OH
- Active Since 07/15/2006
- Last Updated 04/12/2011
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1174549679
Products in Payments
- Non-Covered Product (Drug) $26,941
- Qelbree (Drug) $9,104
- DASOTRALINE (Drug) $8,895
- MYDAYIS (Drug) $5,331
- LATUDA (Drug) $4,762
- TROKENDI XR (Drug) $4,182
- Evekeo (Drug) $4,140
- TRINTELLIX (Drug) $4,043
- Dyanavel XR (Drug) $3,506
- VRAYLAR (Drug) $3,496
- PRISTIQ (Drug) $3,200
- REXULTI (Drug) $2,997
- GOCOVRI (Drug) $2,000
- Azstarys (Drug) $1,800
- IGALMI (Drug) $1,575
- CAPLYTA (Drug) $1,200
- BREXPIPRAZOLE (Drug) $1,113
- Equetro (Drug) $967.10
- GEODON (Drug) $895.74
- NUPLAZID (Drug) $750.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Cleveland
Dr. Sarah Lytle, M.d, M.D
Child & Adolescent Psychiatry — Payments: $1,886
Child & Adolescent Psychiatry $1,886
Dr. Mackenzie Varkula, D.o, D.O
Child & Adolescent Psychiatry — Payments: $1,734
Child & Adolescent Psychiatry $1,734
Diana Sabagh Sabagh, Md, MD
Child & Adolescent Psychiatry — Payments: $1,501
Child & Adolescent Psychiatry $1,501
Pilar Lachhwani, Md, MD
Child & Adolescent Psychiatry — Payments: $438.35
Child & Adolescent Psychiatry $438.35
Dr. Samantha Imfeld, M.d, M.D
Child & Adolescent Psychiatry — Payments: $342.78
Child & Adolescent Psychiatry $342.78
Desimir Mijatovic, Md, MD
Child & Adolescent Psychiatry — Payments: $323.21
Child & Adolescent Psychiatry $323.21